**Drug Warehouse Inspections**

In February 2012, Brian Bilbray wrote HR 4056, a bill that would prevent states from conducting duplicative inspections of drug warehouses and medical device warehouses conducted by the FDA. [Thomas.loc.gov, 2/16/12]

The bill would benefit life science companies and help them get their product to market faster. [North County Times, 2/22/12]

**Companies Lobbying for Bill**

Below is a list of companies that lobbied for the bill.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Client** | **Lobbying Firm** | **Amount Spent** | **First Report Containing Bill** | **Most Recent/Final Report Containing Bill** |
| Advanced Medical Technology Assn | Advanced Medical Technology Assn | $937,755 | [6/30/12](http://soprweb.senate.gov/index.cfm?event=getFilingDetails&filingID=3E2977E6-6438-4693-B448-A65DE4403F56) | [6/30/12](http://soprweb.senate.gov/index.cfm?event=getFilingDetails&filingID=CCBC130C-807F-416A-8C26-B392C20B5C40) |
| Boston Scientific Corp | Boston Scientific Corp | $730,000 | [3/31/12](http://soprweb.senate.gov/index.cfm?event=getFilingDetails&filingID=68044203-3462-41EC-961A-51D5A64AC2DE) | [6/30/12](http://soprweb.senate.gov/index.cfm?event=getFilingDetails&filingID=61744EF2-4179-4ADE-8F30-BE64E636BECC) |
| Consumers Union of the US | Consumers Union of the US | $80,000 | [3/31/12](http://soprweb.senate.gov/index.cfm?event=getFilingDetails&filingID=A03A1539-EA07-49D6-8CFC-7AB965F7DAA5) | N/A |
| Exxon Mobil | Exxon Mobil | $4,170,000 | [3/31/12](http://soprweb.senate.gov/index.cfm?event=getFilingDetails&filingID=97A6B859-802C-4336-9C79-770AF55B1F0D) | **N/A** |

[Lobbying Disclosure Database, accessed 9/21/12]

**Bilbray Took $15,000 from PACs Lobbying for the Bill**

|  |  |  |
| --- | --- | --- |
| **Company** | **Amount** | **Date** |
| Advanced Medical Technology Association PAC | $1,000 | 3/29/11 |
| Advanced Medical Technology Association PAC | $1,000 | 6/07/12 |
| Boston Scientific Corporation PAC | $1,000 | 3/07/11 |
| Boston Scientific Corporation PAC | $1,000 | 4/17/12 |
| Boston Scientific Corporation PAC | $1,000 | 6/13/12 |
| Exxon Mobil Corporation PAC | $5,000 | 7/24/12 |
| Exxon Mobil Corporation PAC | $5,000 | 2/17/12 |
| **TOTAL** | $15,000 |  |

[CQ Money Line, accessed 9/21/12]

Bilbray received $15,000 from companies that lobbied on the bill this cycle. Of the $15,000, $13,000 was donated 5 months after Bilbray introduced the bill.

This cycle, Bilbray took $124,750 from the pharmaceutical industry. [opensecrets.org, accessed 9/21/12]

**Took $37,500 from Companies Benefitting from Bill**

During the 2012 cycle, Bilbray took $37,500 from companies who stood to benefit from the bill. [opensecrets.org, accessed 9/24/12]

|  |  |  |  |
| --- | --- | --- | --- |
| **Company** | **Individuals** | **PAC** | **Total** |
| Millennium Laboratories | $17,500 | $0 | $17,500 |
| Abbott Laboratories | $0 | $10,000 | $10,000 |
| Life Technologies Corp | $10,000 | $0 | $10,000 |
| **TOTAL** | **$27,500** | **$10,000** | **$37,500** |